Delayed DNA double-strand break repair following platin-based chemotherapy predicts treatment response in head and neck squamous cell carcinoma.
View/ Open
Date
2016-09-27ICR Author
Author
Bhide, SA
Thway, K
Lee, J
Wong, K
Clarke, P
Newbold, KL
Nutting, CM
Harrington, KJ
Type
Journal Article
Metadata
Show full item recordAbstract
INTRODUCTION: The aim of this study was to investigate if defective repair of DNA double-strand break (DSB) in head and neck squamous cell carcinoma (HNSCC) could be used as an early predictor of treatment response. METHODS: Tumour biopsy 24-36 h following induction chemotherapy (IC) and pre-treatment biopsies were stained for RAD51 and geminin (S-phase marker) for immunofluorescence in patients with HNSCC. The difference between RAD51 score (percentage of geminin-positive cells that were also positive for RAD51) was calculated for the two specimens. Tumours with a percentage difference of⩽10% were deemed to have repaired IC-induced DSBs, and were classified as 'RAD51 negative'. Response at 3 months post treatment and human papilloma virus (HPV) status were assessed. RESULTS: Thirteen pairs of samples were available for analyses. Three samples were classified as RAD51 negative and 10 as RAD51 positive at 24 h post IC. All of the three patients with tumours classified as RAD51 negative had partial response or progressive disease and the 10 patients with tumours deemed RAD51 positive had a complete response. 100% of the HPV-positive tumours were RAD51 positive and had a complete response. CONCLUSIONS: We have demonstrated that impaired DSB DNA repair may underlie enhanced treatment sensitivity of HPV-positive HNSCC and repair capacity following platinum-induced DNA damage predicts response in HNSCC. This has potential as a biomarker for patient selection in trials of DNA damage response pathway modulation.
Collections
Subject
Humans
Papillomaviridae
Papillomavirus Infections
Carcinoma, Squamous Cell
Oropharyngeal Neoplasms
Organoplatinum Compounds
Neoplasm Proteins
DNA, Neoplasm
Antineoplastic Agents, Alkylating
Antineoplastic Combined Chemotherapy Protocols
Treatment Outcome
Pilot Projects
S Phase
DNA Repair
Rad51 Recombinase
DNA Breaks, Double-Stranded
Chemoradiotherapy
Research team
Targeted Therapy
Language
eng
Date accepted
2016-08-01
License start date
2016-09
Citation
British journal of cancer, 2016, 115 (7), pp. 825 - 830
Publisher
NATURE PUBLISHING GROUP